Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: Results from the Long Island Breast Cancer Study Project

Yu Chen, Marilie D. Gammon, Susan L. Teitelbaum, Julie A. Britton, Mary Beth Terry, Sumitra Shantakumar, Sybil M. Eng, Qiao Wang, Irina Gurvich, Alfred I. Neugut, Regina M. Santella, Habibul Ahsan

Research output: Contribution to journalArticle

Abstract

The genes that are involved in estrogen biosynthesis, cellular binding and metabolism may contribute to breast cancer susceptibility. We examined the effect of the CYP17 promoter T → C polymorphism and its interactions with the reproductive history, exogenous hormone use and selected lifestyle risk factors on breast cancer risk among 1037 population-based incident cases and 1096 population-based controls in the Long Island Breast Cancer Study Project. Overall, there were no associations between the CYP17 genotype and breast cancer risk. Among postmenopausal women, the joint exposure to higher body mass index (BMI) and the variant C allele was associated with an increased risk of breast cancer [odds ratio (OR), 1.60; 95% confidence interval (CI), 1.15-2.22]. The joint exposure to the variant C allele and long-term use of hormone replacement therapy (HRT) (>51 months) was related to an increased risk of breast cancer (OR, 1.51; 95% CI, 0.99-2.31) especially estrogen receptor-positive, progesterone receptor-positive breast cancer (OR, 1.87; 95% CI, 1.08-3.25). Among the control population, the CYP17 variant C allele was inversely associated with long-term use of postmenopausal HRT and a higher BMI in postmenopausal women. In conclusion, the findings suggest that the CYP17 variant C allele may increase breast cancer risk in conjunction with long-term HRT use and high BMI in postmenopausal women.

Original languageEnglish (US)
Pages (from-to)766-771
Number of pages6
JournalCarcinogenesis
Volume29
Issue number4
DOIs
StatePublished - Apr 2008

Fingerprint

Steroid 17-alpha-Hydroxylase
Islands
Life Style
Estrogens
Breast Neoplasms
Genes
Alleles
Body Mass Index
Odds Ratio
Hormone Replacement Therapy
Confidence Intervals
Joints
Reproductive History
Estrogen Replacement Therapy
Population Control
Progesterone Receptors
Estrogen Receptors
Population
Genotype
Hormones

ASJC Scopus subject areas

  • Cancer Research

Cite this

Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk : Results from the Long Island Breast Cancer Study Project. / Chen, Yu; Gammon, Marilie D.; Teitelbaum, Susan L.; Britton, Julie A.; Terry, Mary Beth; Shantakumar, Sumitra; Eng, Sybil M.; Wang, Qiao; Gurvich, Irina; Neugut, Alfred I.; Santella, Regina M.; Ahsan, Habibul.

In: Carcinogenesis, Vol. 29, No. 4, 04.2008, p. 766-771.

Research output: Contribution to journalArticle

Chen, Y, Gammon, MD, Teitelbaum, SL, Britton, JA, Terry, MB, Shantakumar, S, Eng, SM, Wang, Q, Gurvich, I, Neugut, AI, Santella, RM & Ahsan, H 2008, 'Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: Results from the Long Island Breast Cancer Study Project', Carcinogenesis, vol. 29, no. 4, pp. 766-771. https://doi.org/10.1093/carcin/bgn042
Chen, Yu ; Gammon, Marilie D. ; Teitelbaum, Susan L. ; Britton, Julie A. ; Terry, Mary Beth ; Shantakumar, Sumitra ; Eng, Sybil M. ; Wang, Qiao ; Gurvich, Irina ; Neugut, Alfred I. ; Santella, Regina M. ; Ahsan, Habibul. / Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk : Results from the Long Island Breast Cancer Study Project. In: Carcinogenesis. 2008 ; Vol. 29, No. 4. pp. 766-771.
@article{7d9b63f7fb0b43a99a2c7797d0b6b868,
title = "Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: Results from the Long Island Breast Cancer Study Project",
abstract = "The genes that are involved in estrogen biosynthesis, cellular binding and metabolism may contribute to breast cancer susceptibility. We examined the effect of the CYP17 promoter T → C polymorphism and its interactions with the reproductive history, exogenous hormone use and selected lifestyle risk factors on breast cancer risk among 1037 population-based incident cases and 1096 population-based controls in the Long Island Breast Cancer Study Project. Overall, there were no associations between the CYP17 genotype and breast cancer risk. Among postmenopausal women, the joint exposure to higher body mass index (BMI) and the variant C allele was associated with an increased risk of breast cancer [odds ratio (OR), 1.60; 95{\%} confidence interval (CI), 1.15-2.22]. The joint exposure to the variant C allele and long-term use of hormone replacement therapy (HRT) (>51 months) was related to an increased risk of breast cancer (OR, 1.51; 95{\%} CI, 0.99-2.31) especially estrogen receptor-positive, progesterone receptor-positive breast cancer (OR, 1.87; 95{\%} CI, 1.08-3.25). Among the control population, the CYP17 variant C allele was inversely associated with long-term use of postmenopausal HRT and a higher BMI in postmenopausal women. In conclusion, the findings suggest that the CYP17 variant C allele may increase breast cancer risk in conjunction with long-term HRT use and high BMI in postmenopausal women.",
author = "Yu Chen and Gammon, {Marilie D.} and Teitelbaum, {Susan L.} and Britton, {Julie A.} and Terry, {Mary Beth} and Sumitra Shantakumar and Eng, {Sybil M.} and Qiao Wang and Irina Gurvich and Neugut, {Alfred I.} and Santella, {Regina M.} and Habibul Ahsan",
year = "2008",
month = "4",
doi = "10.1093/carcin/bgn042",
language = "English (US)",
volume = "29",
pages = "766--771",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk

T2 - Results from the Long Island Breast Cancer Study Project

AU - Chen, Yu

AU - Gammon, Marilie D.

AU - Teitelbaum, Susan L.

AU - Britton, Julie A.

AU - Terry, Mary Beth

AU - Shantakumar, Sumitra

AU - Eng, Sybil M.

AU - Wang, Qiao

AU - Gurvich, Irina

AU - Neugut, Alfred I.

AU - Santella, Regina M.

AU - Ahsan, Habibul

PY - 2008/4

Y1 - 2008/4

N2 - The genes that are involved in estrogen biosynthesis, cellular binding and metabolism may contribute to breast cancer susceptibility. We examined the effect of the CYP17 promoter T → C polymorphism and its interactions with the reproductive history, exogenous hormone use and selected lifestyle risk factors on breast cancer risk among 1037 population-based incident cases and 1096 population-based controls in the Long Island Breast Cancer Study Project. Overall, there were no associations between the CYP17 genotype and breast cancer risk. Among postmenopausal women, the joint exposure to higher body mass index (BMI) and the variant C allele was associated with an increased risk of breast cancer [odds ratio (OR), 1.60; 95% confidence interval (CI), 1.15-2.22]. The joint exposure to the variant C allele and long-term use of hormone replacement therapy (HRT) (>51 months) was related to an increased risk of breast cancer (OR, 1.51; 95% CI, 0.99-2.31) especially estrogen receptor-positive, progesterone receptor-positive breast cancer (OR, 1.87; 95% CI, 1.08-3.25). Among the control population, the CYP17 variant C allele was inversely associated with long-term use of postmenopausal HRT and a higher BMI in postmenopausal women. In conclusion, the findings suggest that the CYP17 variant C allele may increase breast cancer risk in conjunction with long-term HRT use and high BMI in postmenopausal women.

AB - The genes that are involved in estrogen biosynthesis, cellular binding and metabolism may contribute to breast cancer susceptibility. We examined the effect of the CYP17 promoter T → C polymorphism and its interactions with the reproductive history, exogenous hormone use and selected lifestyle risk factors on breast cancer risk among 1037 population-based incident cases and 1096 population-based controls in the Long Island Breast Cancer Study Project. Overall, there were no associations between the CYP17 genotype and breast cancer risk. Among postmenopausal women, the joint exposure to higher body mass index (BMI) and the variant C allele was associated with an increased risk of breast cancer [odds ratio (OR), 1.60; 95% confidence interval (CI), 1.15-2.22]. The joint exposure to the variant C allele and long-term use of hormone replacement therapy (HRT) (>51 months) was related to an increased risk of breast cancer (OR, 1.51; 95% CI, 0.99-2.31) especially estrogen receptor-positive, progesterone receptor-positive breast cancer (OR, 1.87; 95% CI, 1.08-3.25). Among the control population, the CYP17 variant C allele was inversely associated with long-term use of postmenopausal HRT and a higher BMI in postmenopausal women. In conclusion, the findings suggest that the CYP17 variant C allele may increase breast cancer risk in conjunction with long-term HRT use and high BMI in postmenopausal women.

UR - http://www.scopus.com/inward/record.url?scp=41849119124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41849119124&partnerID=8YFLogxK

U2 - 10.1093/carcin/bgn042

DO - 10.1093/carcin/bgn042

M3 - Article

VL - 29

SP - 766

EP - 771

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 4

ER -